FDA accelerates review of Pfizer and Bristol's anti-coagulant Eliquis

11/29/2011 | Wall Street Journal, The · Reuters

The FDA granted priority-review designation to Pfizer and Bristol-Myers Squibb's Eliquis, or apixaban, and is expected to decide on the anti-clotting drug by March 28, 2012. The drugmakers aim to launch Eliquis for stroke prevention among patients with atrial fibrillation. If approved, Eliquis will be the third such treatment, after Bayer and Johnson & Johnson's Xarelto and Boehringer Ingelheim's Pradaxa.

View Full Article in:

Wall Street Journal, The · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN